Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibikase Therapeutics, Inc.IKT · Entity 5838 | Cheif Financial Officer | March 01, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibikase Therapeutics, Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2023-03-01 | Direct | 90,000 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 90,000 · Balance 90,000 F1: One-third of the options will vest and become exercisable on 3/1/2024, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2024, subject to continued employment through each such vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 48,091 |
Reported balance
Holding disclosure · report date 2023-03-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 48,091 |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of the options will vest and become exercisable on 3/1/2024, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2024, subject to continued employment through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 3, 2023 22:00 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000899243-23-007009 · doc4.xml · derivative · entry 2 FRATTAROLI JOSEPH · CIK 0001272668 · Cheif Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2023-03-01 F1 · derivative.exercise_date: One-third of the options will vest and become exercisable on 3/1/2024, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2024, subject to continued employment through each such vesting date. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:54 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | PurchaseCommon Stock | 3,948 | $0.64 | $2,542.51 |
DisclosureSEC source: 0000899243-22-019219 · doc4.xml · nonDerivative · entry 1 FRATTAROLI JOSEPH · CIK 0001272668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,091 Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 01:22 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000899243-22-010333 · doc4.xml · derivative · entry 2 FRATTAROLI JOSEPH · CIK 0001272668 · Cheif Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2029-03-07 F1 · derivative.exercise_date: One-third of the options will vest and become exercisable on 3/7/2023, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2024, subject to continued employment through each such vesting date. Read SEC document |
| March 07, 2022 Filed Mar 21, 2022 20:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000899243-22-011699 · doc4.xml · derivative · entry 2 FRATTAROLI JOSEPH · CIK 0001272668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2029-03-07 F1 · derivative.exercise_date: One-third of the options will vest and become exercisable on 3/7/2023, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2023, subject to continued employment through each such vesting date. F2 · derivative.exercise_date: The original Form 4, filed on March 9, 2022, is being amended by this Form 4 amendment to correct an error that misreported that the 24 equal monthly installments mentioned in footnote 1 would begin on the first day of April 2024, rather than the first day of April 2023 as intended. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 02:52 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | ConversionConvertible Note · Derivative | Not disclosed | $0.00 Strike: $10.00 | $441,431.52 |
DisclosureSEC source: 0001104659-20-140307 · tm2039455d1_form4.xml · derivative · entry 3 FRATTAROLI JOSEPH · CIK 0001272668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Consulting, Inc. Disclosed balance after: 0 Underlying: Common Stock · 44,143 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 02:52 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | ConversionCommon Stock | 44,143 | $10.00 | $441,430.00 |
DisclosureSEC source: 0001104659-20-140307 · tm2039455d1_form4.xml · nonDerivative · entry 1 FRATTAROLI JOSEPH · CIK 0001272668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Consulting, Inc. Disclosed balance after: 44,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 30, 2020 02:52 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140307 · tm2039455d1_form4.xml · derivative · entry 2 FRATTAROLI JOSEPH · CIK 0001272668 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-22 F1 · derivative.exercise_date: One-third of the option will vest and become exercisable on 12/22/2021, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of the month beginning January 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.